Good day, everyone, and welcome to the Sensus Healthcare Fourth Quarter 2020 Earnings Conference Call. At this time, I am pleased to hand it over to your host, Ms. Kim Golodetz. The floor is yours.

Thank you. This is Kim Golodetz with LHA. Thank you all for participating in today’s call. Joining me from Sensus Healthcare are Joe Sardano, Chief Executive Officer, and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today’s call contain forward-looking statements within the meaning of federal securities laws. All statements other than historical facts that address activities Sensus Healthcare assumes, plans, expects, believes, intends or anticipates, and other similar expressions will, should, or may occur in the future are forward-looking statements. The forward-looking statements are management’s beliefs based on currently available information. Sensus Healthcare undertakes no obligation to update or revise any forward-looking statements, except as required by law. All forward-looking statements are subject to risks and uncertainties, including the continuation and severity of the COVID-19 pandemic and its impact on sales and marketing, as described in the company’s Forms 10-K and 10-Q. During today’s call, there will also be reference to certain non-GAAP financial measures. Sensus believes these measures provide useful information for investors, yet should not be considered a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today’s financial results press release. With that said, I’d like to turn the call over to Joe Sardano. Joe?

Thank you, Kim, and good afternoon, everyone. Thank you all for joining us. And once again, I express my hopes that you have all remained healthy and are keeping safe and that before too long, we will be able to put the COVID-19 pandemic behind us. We are pleased with our fourth-quarter revenues of $5.1 million, which were well above our third-quarter revenues of $1.6 million. This increase reflects the gradual reopening of the economy in certain geographic areas as well as our continued dedication to our physician customers and preparation for the resumption of normal practice activities. While our business continues to be impacted by the pandemic, the cautious reopening of regional economies allows Sensus to resume sales. We were delighted to ship 18 SRT systems during the quarter, including 12 domestic direct sales and 3 to China. On a year-over-year basis, our revenues continued to reflect the impact of the pandemic as compared to Q4 2019, which were well below the $8.5 million we recorded a year ago. We continue to take all the steps necessary to keep Sensus on firm footing and prepare our company for rapid growth when the pandemic subsides. This is a credit to the entire Sensus team for their cooperation and discipline in adhering to our strict financial guidelines established at the beginning of 2020. To that end, reflecting our keen attention to operating expenses, we generated net income of $1 million for the quarter, which is a positive finish to a very challenging year. We are cautiously optimistic that markets will show modest recovery during the first half of 2021, and we plan to step up select hiring in our sales organization. During the fourth quarter, we received news that we had been waiting many years to receive, the Centers for Medicare & Medicaid Services, or CMS, increased reimbursement for the main SRT code along with meaningful increases in Evaluation & Management or E&M codes. We are delighted with the progress following years of lobbying. Specifically, CMS issued new reimbursement amounts for CPT treatment code 77401 and E&M codes. The combination of these increased values provides SRT users as much as a 50% increase over the reimbursement values of the past several years. In addition, codes were revalued upward for the ultrasound capability in our SRT-100 Vision systems. We are delighted that our physician customers will now be more fairly reimbursed for a procedure with outcomes at least comparable to surgery without the potential complications. We also believe new reimbursement amounts will catalyze additional physician interest in adding SRT to their treatment armamentarium, especially after working through the pandemic when surgeries were halted while SRT units continued to treat. We are now tasked with educating our market of these new codes. To date, we have penetrated only about 2% of the U.S. market. So clearly, there is plenty of upside for growth. We are also delighted that so many key opinion leaders advocated for us with CMS, highlighting the efficacy and safety of SRT. The American Cutaneous Oncology Society, in particular, was most helpful, working alongside Sensus with the AAD and CMS. We have a lot of people to thank for believing in us and our technology. Also during the fourth quarter, there were two separate peer-reviewed publications highlighting the efficacy of SRT against the recurrence of keloid scars. The first study I discussed on our last conference call in November. That one showed keloidectomy followed by SRT had an approximate 10% recurrence rate compared with an expected recurrence rate of more than 80% following surgical excision alone. The other was published by the Journal of Clinical and Aesthetic Dermatology and was a retrospective study showing that a single low dose of SRT following excision of 14 keloids had an approximate 6.25% recurrence rate at 6 months and for the 10 patients available for follow-up at 24 months, none of the keloids had recurred. These are tremendous data points that impact people with skin of color. They finally have a choice for their keloid problems. We also exhibited virtually at the South Beach Symposium held in early February. Over 1,000 dermatologists were registered for this 4-day conference with a faculty of renowned physicians presenting the latest in clinical dermatology. Although COVID-19 impacted sales, it also presented an opportunity for Sensus to offer treatment for pneumonia in COVID-19 patients by delivering superficial radiation therapy to the lung. During the fourth quarter, we shipped an SRT system to Holy Name hospital in Teaneck, New Jersey. Holy Name has been at the forefront of COVID-19 therapy since the start of the pandemic. We expect to receive data on the efficacy of our system for this use during the second quarter. In evaluating this opportunity to help our frontline workers and patients, history showed a very successful approach to treating pneumonia with radiation going back almost 75 years. We engaged an outside physics laboratory to evaluate our radiation and provide us with a non-biased opinion on whether or not our radiation can penetrate the body enough to treat the lungs. They published a paper that provided us the confidence that our SRT technology was capable. In presenting this finding to Holy Name Medical Center, they agreed to acquiring the SRT-100 Vision to treat the lung. This is the hospital in Teaneck, New Jersey that has been at the forefront of the epidemic while performing drug discovery with major drug companies who now have FDA approvals. Our SRT systems are well suited for COVID-19 because they’re portable and allow for bedside treatment in the ICU rather than transporting patients to a cancer treatment center for radiation therapy and possibly exposing vulnerable oncology patients to the virus. We will introduce a family of 4 FDA-cleared aesthetic lasers powered by our Sentinel IT Solutions software in April. Sentinel provides asset management and HIPAA-compliant patient data and storage capability and also contains software necessary to support shared service models, including direct patient billing. We will be integrating these lasers into our Sensus Laser Aesthetic services. This is our mobile aesthetic laser division that we expect will become a meaningful source of revenue growth, particularly as we roll out disruptive rental strategies during the first quarter of 2021. These strategies are designed to generate consistent revenue for Sensus while providing physician customers with access to multiple different lasers. We’re also looking at expanding our mobile aesthetic laser business beyond Florida via strategic transactions. Sentinel IT has started to generate high-margin recurring revenue. Although still in its life cycle, Sentinel holds significant promise as an integrated feature, not only for the new lasers but also for the SRT-100+ and SRT-100 Vision. Turning now to our international efforts, business in China picked up during the fourth quarter with the sale of three systems. Plus, as of January 1, 2021, we have a new distribution partner for China and Hong Kong. Our new VP of international sales has developed an extensive network of prospects in China, and we’re optimistic that China represents an excellent growth opportunity. This year, we will be engaged with the Chinese health authority in renewing our license for another 4 years. This will be an expensive endeavor and require almost the entire year to accomplish. This will be our third renewal. In addition, we are finalizing a new distributor in Taiwan and are preparing Sculptura for the regulatory process in China. Sculptura is our anisotropic radiation therapy with beam sculpting capabilities and robotic respiratory tracking for up to 17 different indications. We announced earlier this week that we were granted an important U.S. patent for Sculptura, which describes the method of beam splitting and sculpting. This patent covers 31 separate claims that deal with how our electron beam generator is able to sculpt and direct X-rays precisely where they are needed. The technology that’s embedded in our Sculptura system differs from conventional intraoperative radiation therapy in its ability to control the radiation beam and has a longer useful operating life. Ours is the first device in the world with this capability, and we believe it opens new doors for the delivery of radiation to treat solid tumors of all kinds. In addition, there may be use for this technology in devices other than Sculptura as well, providing potential licensing opportunities. As I mentioned last quarter, we have been making solid progress with commercializing the Sculptura system and showcasing its unique technology capabilities when the pandemic stopped us in our tracks. Also, research by the luminary hospitals engaged to provide data to support our marketing efforts for Sculptura came to a standstill. While breast cancer appears to be the initial focus of these cancer centers, we expect Sculptura ultimately will be used for up to 17 different oncology indications. We are hopeful sales will resume later this year. With that, I will turn the call over to Javier Rampolla, our CFO, who will go over our Q4 and full-year financial results in more detail. Javier?

Thanks, Joe. It’s a pleasure to be speaking with all of you this afternoon. As Joe mentioned, revenues for the fourth quarter of 2020 were $5.1 million, and this compares with revenues of $8.5 million for the fourth quarter of 2019. Revenues for the fourth quarter of 2020 were derived from the sale of 18 SRT systems including 12 direct domestic sales and 3 systems to China as well as service contracts and our new mobile laser business. The decrease from the fourth quarter of 2019 reflects a lower number of units sold due to the impact of COVID-19. Gross profit for the fourth quarter of 2020 was $3.2 million or 63% of revenue compared with $5.5 million or 64% of revenue for the fourth quarter of 2019. Selling and marketing expense for the fourth quarter of 2020 was $1.3 million, down from $2.5 million for the fourth quarter of 2019. The decrease was primarily due to a reduction in trade show expenses and a lower sales commission. General and administrative expense for the fourth quarter of 2020 was $0.8 million compared with $1.1 million for the fourth quarter of 2019. The decrease primarily reflects the impact of bad debt expenses in 2019. Research and development expense for the fourth quarter of 2020 was $0.8 million compared with $0.9 million for the fourth quarter of 2019. The slight decrease was mainly due to lower expenses related to the Sculptura development as commercial production started. Net income for both the fourth quarter of 2020 and 2019 was $1 million or $0.06 per diluted share. Adjusted EBITDA, defined as earnings before interest, taxes, depreciation, amortization and stock compensation expense, for both the fourth quarter of 2020 and 2019 was $1.3 million. Turning briefly now to the full-year financial results, revenues for 2020 were $9.6 million, and this compares with revenue of $27.3 million for 2019. The decrease is primarily due to the lower number of units sold as a result of COVID-19. Selling and marketing expense decreased to $5.3 million for 2020 from $9.1 million in the prior year, primarily due to cancellation of trade shows due to COVID-19, a decrease in commission expense due to lower sales, and reduced spending on marketing activities. General and administrative expense was unchanged at $4 million for both years. Research and development expense was $4.2 million for 2020 compared with $6.4 million for 2019. The decrease was primarily due to lower spending as the Sculptura project entered commercial production during 2020. The net loss for 2020 was $6.8 million or $0.42 per share compared with a net loss for 2019 of $1.7 million or $0.10 per share. Adjusted EBITDA for 2020 was negative $5.8 million compared with negative $0.8 million for 2019. Cash and investments were $14.9 million as of December 31, 2020, compared with $15.5 million as of December 31, 2019. The company had a small long-term debt and no outstanding borrowings under its revolving line of credit, both during 2020 and as of December 31, 2020. We’re confident that with our continued attention to expenses, along with current cash and access to our existing revolving credit agreement, we continue to be financially well positioned to support our expected growth during 2021. With that, I will turn the call back over to Joe.

Thank you, Javier. I am so very proud of our staff and the way we kept our focus on customers and patients throughout the pandemic. I think you can see from our activities that the team continued to push the envelope in many areas. We believe the worst is now behind us and that we are well positioned to resume the growth trajectory that was interrupted almost exactly 1 year ago. We’re looking forward to 2021 with higher reimbursement amounts for SRT, an elevated presence for Sculptura and commercial sales, as well as the contribution from our newly acquired companies, Sensus Laser Aesthetic Solutions. I will remind you that our products have enormous room to grow. Our SRT systems are well positioned in a large market consisting of about 14,000 dermatologists and 1,000 Mohs surgeons in the U.S., representing more than 7,500 offices and growing, not to mention a further 6,500 plastic surgeons and 5,500 radiation oncologists. We provide a compelling alternative to surgery for millions of patients and arguably the only solution to prevent the recurrence of keloids following surgical excision. With those comments, I would like to thank you for your time and attention. And now operator, we are ready to take questions. Thank you.

Thank you. Our first question will come from Alex Nowak at Craig-Hallum Capital.

Hey, good afternoon everyone. This is Trent McCarthy on for Alex. First off, I just wanted to congratulate you guys on getting the increase in reimbursement from CMS that was great to see.

Thank you, Trent.

One quick question on that front, what is the percentage of like – actually what percentage of the beat this quarter would you attribute to people getting excited for this?

The fourth quarter, I would have to say that it was very, very little only because we couldn’t announce it, market it or anything, because it didn’t become – it wasn’t announced by CMS until the very first week of December. So, it didn’t give us a whole lot of chance to use it as a selling tool. Most of our sales were earlier in the quarter. And then of course, CMS doesn’t make an announcement that says, oh, by the way, everybody in dermatology, you have an increase in SRT reimbursement. We have to physically take that bull by the horns and go out into the market and now tell the customers exactly – or the prospects exactly what that reimbursement is. So, we have to educate them and train them on our own. So, that’s a lot of heavy blocking and tackling.

How long do you expect for that to really start to ramp and start to materialize, if you will?

Well, we have partners such as Pinnacle, who we use as our main consultant on this where customers can call them up and find out exactly what that reimbursement is, but we always projected that the first 6 months of the year is going to be the heavy part and hopefully, that we will start seeing some revenues as a result of that in the second half. And we will see business picking up in the second half, but again, a lot of it is reliant on the pandemic and how much – how aggressive the dermatologists are going to be within their own practices.

Got it. That’s helpful. Just pivoting real quick over to the recurring side, you guys are expanding these rental businesses to begin offering SRT-100 on a recurring basis, what is the latest with that and also the latest on expanding into other rental markets?

Well, we acquired these two companies because of the opportunity we felt in growing that rental business, not just to have daily rentals or procedure rentals, but also weekly, monthly and yearly rentals. And we have come across several prospects that are also interested in superficial radiation therapy as being part of those rentals. Now there are a lot of things that you have to go through to satisfy the regulatory people in each and every one of the states, but the fact that there is interest there, I think is a good lead in with a lot of these customers. And we will see where they end up going, whether they go with a rental or whether they actually buy because of the new reimbursement codes that are out there. But either way, it gives us another opportunity and another topic to discuss with potential prospects who may not have been interested in the past. So this is an exciting opportunity for us. And with regard to the laser rentals, we think that organically, we are going to see some business increase in that as we get back to where we were pre-COVID, and that might happen sooner than not because of the type of patient that we have involved there as well as the fact that it’s a different business model. So, we are looking forward to developing that business into a much richer environment.

Got it. Thanks for the questions.

Thank you, Trent.

We will move next to Scott Henry at ROTH Capital.

Thank you. Good afternoon and a really strong quarter, Joe. Congratulations there.

Thank you, Scott.

Again, I have a couple of questions. First, we are a couple of months or almost 2 months into Q1, I know you tend to be strong in Q4 anyways. How should we think about Q1 sequentially from these levels at Q4? I don’t know if I would expect it to match this, but I would think perhaps it will be stronger than what we have seen in Q2 and Q3; just wanted to get your thoughts on that?

Well, number one, it better be stronger than Q1 or Q3, because we are planning on it. And listen, it’s a very, very good question and it’s difficult to answer, but we see our market opening up a little in those regions where there are a majority of areas in the country that are open in spite of COVID versus the major lockdowns that exist in other parts of the country. And we have got another point of topic to discuss, and that being the new reimbursement code. So, we are going to go through a series of Zoom meetings with prospects and our existing customers to talk about this. It’s really not us, but it’s the American Cutaneous Oncology Society that will be hosting this with presentations to let everybody know what those reimbursement codes are and then of course Pinnacle is the main focus of our customers where they can follow up with those folks on a regular basis and understand exactly what that reimbursement is. So, we are hoping that this catches on sooner rather than later, and we see people that are interested again. To what extent that they are going to buy, we are going to push real hard to do a whole lot better than we did in the previous quarters, 1, 2 and 3 of last year and hopefully replicate what we did in Q4 for 2019. It’s a tall order. And I don’t think anybody can tell us that everything is going to be normal anytime soon, but we are going to push as hard as we can.

Okay, great. Thanks for that color. And then also on the income statement, gross margins bounced back strong in Q4. I am sure a lot of that was volume, but do you think we could maintain gross margins at that level assuming that you do still have a bit higher volume than we saw in the first part of 2020?

The last 4 or 5 years, the sales team has done an excellent job in maintaining our average selling prices, including whatever we sold during the COVID period. And so our customers are absolutely realizing how important this technology and how valuable this technology is. And it’s not a question of the price they pay, it’s more of a question of how do we support them and how do we get patients, because there are plenty of patients out there. So, I think that there is a value that’s been established for the product. And I think that we should be able to maintain those margins of between 62% and 65% as we have had for the last 4, 5, 6 years, and it’s just a matter of how many units can we sell in order to stay up there. That’s the big deal as we have seen this quarter versus the previous quarters.

Okay. And then operating expenses, if we combine the three categories together, they bounced around a lot in 2020, but the question is, but as a whole, if we take the yearly operating expenses for 2020, would you expect 2021 to look similar?

The neat thing of what – and the timing of the R&D that we have had for the past several years is the fact that I would say, 90% to 95% – 99% of the R&D is behind us, because those products have been developed, not only Sculptura but also the development of lasers that we are going to be introducing around April 1. So, my expectation, I think Javier, I will let you discuss it as well. We went from $6.5 million in 2019 to about $4.5 million in 2020. And I am hoping that we should be considerably a whole lot less than $4.5 million in 2021. What I am looking forward to is spending a whole lot more money on sales and marketing expense, especially in the commission side. We want our people to make a lot of money, which means that they are going to be selling a lot of product.

That’s correct, Joe. We expect selling and marketing to be a little bit higher for 2021. G&A will sustain at about $4 million, and then R&D definitely, we want to push that down to a decrease from 2020 as well.

Okay, great. And in the past, you have broken out SRT-100 versus the Vision, it’s not that critical, but I don’t know if you have those numbers available?

Javier, I think you have those numbers.

I do have the numbers. We shipped out 8 Vision systems in Q4.

Okay, great. Then that should do it for me. Thank you for taking the questions.

Thanks, Scott. Appreciate it.

We will take our next question from Anthony Vendetti of Maxim Group.

Thanks. Good afternoon. How are you doing, Joe?

Hey, Anthony. How are you?

Very well. Thanks. Just you mentioned on the last question there, you brought up the fact that there is going to be some new lasers probably around April 1. Can you talk about that? Are those proprietary Sensus lasers? Is that going to complement the rental strategy that you had, just a little more color on that?

Sure. I will describe the lasers to you. We will have a CO2 laser, a Q-Switched laser, a pico laser as well as an IPL laser. I’m not going to get into the specific details of each one, but they are pretty common lasers that will be out there. They’ll be available to sell by our direct sales team that’s already selling SRT and talking to the same customers. And we will integrate these systems over a period of time to be included in our laser services division, which is providing the rentals. The key thing, as we’ve been talking about with all of these lasers, was implementing the Sentinel program into this and the Sentinel feature, which provides – and it will be exclusive to our company in this market, whether it’s SRT or lasers. That being the IT solutions piece that provides an asset management program to all of our customers. So a lot of the customers that have multiple sites can manage each one of these lasers as well as SRT remotely from a workstation, a laptop, iPad, iPhone or even an iWatch. And so all of this – and that was the length of time that it took to integrate these, because a lot of these lasers just didn’t have that capability, and that was the big thing that our engineering team has been doing over the last couple of years. So we’re excited to be bringing these out. We do have models that we’re presenting to our marketing team. We’ll be taking pictures, developing brochures and having it all ready for an April 1 launch. If we can do it sooner, we could, but we’re looking at April 1 as being a right thing to do because we’ll have all the support data behind it.

Excellent. Okay, great. And then on the 18 systems shipped, 12 domestic, 3 China, the other 3, obviously would have to be international as well. Were they – what other countries did you sell into?

I’ll let Javier talk to that because out of the 18, 2 were not counted as revenue, but they were shipped. They’ll be counted as revenue for this quarter, and one of them was a Vision. One of them had gone to a hospital, which I think everybody understands they don’t quite move as fast as a dermatology practice. So I’ll let – go ahead, Javier. You can talk about...

Correct. So in Q4, we shipped 8 Vision systems, of which we had to defer 1, 3 SRTs that went to China, and then 7 SRT that we shipped to the U.S. domestically. And out of those 7, we also deferred one of them due to assessment losses and all that. So a total of 18 units shipped in the quarter.

Okay, excellent. So maybe just, Joe, if you could talk a little bit then just to shift gears to the COVID-19. What you’re doing there in Teaneck, New Jersey? Is – do you see that as an opportunity commercially beyond COVID-19, assuming, obviously, COVID-19 starts to phase somewhat over the rest of ‘21? Do you see that as an opportunity, though, for the treatment of pneumonia post COVID-19? How do you look at that opportunity?

It’s an excellent question, and I’m hoping that you’re right that COVID-19 in 2021 gets behind us. But here’s what we did. And we started this about 6, 7 months ago as far as looking at this. Again, we looked back in the history books and the predecessor to our SRT product was the orthovoltage unit. The orthovoltage unit did everything that we thought it would do because that was the ultimate radiation device at that time. And one of the things – the primary way to treat pneumonia in the lung was radiating the lung. And the orthovoltage unit was the primary source of doing it. When drugs started coming into play and other medications to help clear lungs and pneumonia and things like that, in the ‘70s, it became lesser used, obviously. And so therefore, people started going to those other medications, if you will, to clear up pneumonia. When we started looking at COVID-19, we said, well, if it was impactful for pneumonia in the lung because that’s what COVID-19 is, it’s just an expansion or extension of pneumonia, I’m wondering if our radiation would be helpful. And so we contracted with an independent outside physics organization who took a look at our radiation and the penetration capability of our system and said, your radiation would penetrate into the lungs and provide an equal distribution of radiation, sufficient enough to clear pneumonia in the lung. And so they ended up – because of that, they ended up writing an independent paper on that. And so we took that paper. And because of my past experience with GE Medical Systems, Teaneck, New Jersey was an important part of our life when we introduced Positron Emission Tomography back then and PET/CT scanning. And one of the chief investigators who is still there and in charge of one of the major departments, I discussed it with her. And she said, we are the epicenter of COVID-19 here in New Jersey. We’re just overwhelmed and inundated with COVID patients, and we would be very, very happy to take a look at anything that might be able to help us. And she recalled the fact that pneumonia was treated with the older orthovoltage units. So with that being said, we made presentations of the independent study to the doctors of the hospital, the radiation oncologists, the pulmonologists, the radiologists, the administration of the hospital. And they came back after the presentation and said anything is worth it. If we could save a life, it’s worth it. So we want to do it. So now the next thing that we had to come up with was how do we find the fact that we need to have a shield. And so we had to find a place somewhere in the world that can manufacture a mobile shield. And this is what I’m going to say that I think is very, very important. This was another part of why we were looking into this. We had discovered that there are about a dozen facilities in the United States headed up by AMRI, by the James Cancer Center at Ohio State University, Miami Cancer Institute. They are doing studies under an IRB, and they were using radiation – low-dose radiation to treat COVID-19. However, that low-dose radiation came from their linear accelerators in their cancer centers. And if you go through the papers that have been published by them so far, there is not a large number of patients that they have done. And the reason being is they have seen this as a major obstacle in bringing COVID patients, which are highly infected, to an area or a department filled with cancer patients whose immune systems are usually at the lowest and infecting those rooms with COVID. And they found out that cleaning those rooms, disinfecting those rooms, which puts downtime on those rooms, impacts their cancer centers. And if they could only find a way to treat the patient bedside and we are the solution if it works. And so it was easy for me to call a trusted physician that we had past experiences with to see if this thing would work. And because of the number of patients that they had, they said they wanted to work it because this makes a lot of sense. They were originally invited to be part of that initial study, and their pulmonologists refused because they didn’t want those patients in the cancer center. So I don’t know if this will be the solution. They will decide if it’s a solution, but it’s certainly an opportunity. And then the last question that you had, how would this work? I don’t think COVID is going away. I think COVID is going to be part of the new standard. It’s going to be part of our life for the rest of our life. There was an article, I think, yesterday or today, that said since COVID has come, the flu has gone away. There aren’t any flu symptoms. So it’s COVID. Now instead of having an annual injection or vaccine for the flu, we’re going to have two injections for the COVID from either Pfizer or someplace else. And if they can get it down to one where it’s efficient, that will be fine. But in my opinion, if you’re in an ICU and you’ve got a problem, regardless of the vaccine, because these are for patients that the vaccine didn’t help, it could be possible that every hospital in the world needs one of these machines because this is a pandemic that’s worldwide. And so this is a very inexpensive way of treating COVID patients around the world. So if it works, it’s going to be big. If it doesn’t work, it’s a good try.

Yes. It’s just an extra shot on goal. Okay. And then just lastly on...

That’s the best way to put it. You’re a hockey guy.

There you go. Sculptura, now that we’re into 2021 – and I agree with you. I don’t think COVID is going away, but hopefully, it starts to circulate at a much lower level for the rest of this year, if vaccination rates increase. Sculptura – that’s something we’ve discussed for a while in 2020. That will dampen new sales for that. Do you feel like the pipeline for that has improved? How should we view Sculptura in 2021?

Yes. We had a face-to-face visit with our team and the UPenn team in January. Our management team decided to go and see them regarding all of the engineering that we were looking at. And we had a face-to-face conversation based on obligations at both sides to meet. We see in their faces, in their eyes, and they have indicated they are more anxious than ever to get going with the Sculptura system. The pandemic is still impacting the resources, but they are also seeing it subside and getting more involved in the Sculptura. I would have to say from my own predictions, and we’ll follow up with meetings with them. But my own sense is that I think that we might see some movement on their side in the second quarter. I’m thinking that we’ll have patients treated in the third quarter. And I will also tell you this; they consistently are getting calls from other sites wanting to know what’s going on because of their interest. Just this week alone, I’ve had two separate phone calls with other facilities in the country that are wanting to know what’s going on with this, even to the point where they want to push for a Zoom meeting presentation, not just from us, but they also want to have the ability to talk to the UPenn people. And these are things that I think are going to be conducted over the next 3 to 6 months. And I think that they are anxious to get going. And I think that they’ll get going. And I’m thinking that we might have an opportunity to make one extra sale this year, which I think would be huge for us. So we’re pushing for that because I think we’ve got prospects that are interested.

Okay, excellent. Thanks, Joe. Thank, Javier. Appreciate it. I will be back in the queue.

Thanks. Thanks, Anthony, hope to see you soon.

Thank you.

We will now move to Ben Haynor at Alliance Global Partners.

Good afternoon, gentlemen. Thanks for taking my questions.

Thanks, Ben. I am being on.

Yes. No problem, Joe. First for me, just with the system you have out there at Holy Name and kind of – it was great to hear the background of the kind of the orthovoltage and how you came across the opportunity and were able to do the research and get it out there with the past relationship. But have you seen any other incoming interest from folks once that was announced and kind of the light bulbs go off and other folks had?

Yes. And we have an opportunity at several other centers, some not as – how can I put it? Not as reputed as Holy Name, but just to give you an idea. In rural Tennessee, a regional community hospital that’s very, very interested, and they talk to people at Holy Names because we connected them there. And they can’t wait for results from Holy Names because they are inundated with a lot of COVID-19 patients. And I think we know that within the last 4 or 5 months, there has been a major spike in Tennessee, whereas before, it was pretty quiet. But this is a hospital that has 600, 700 patients in ICU, where they have turned other floors into ICU. So, huge opportunity there, opportunities at other hospitals that are awaiting to see how this turns out because it’s not optimum to be treating those patients in the cancer center, and this is something that I think everybody wants to see successful.

Makes sense. And then you mentioned coming up with the mobile shield. Does that help you with state regulators in other jurisdictions or other states with just the regular-type installs?

We hope. We hope. But you have to remember that because of COVID, a lot of state regulators – and we had to check with the state regulators of New Jersey, have softened a lot of the regulations due to COVID. So I don’t expect that it will be there forever. But I think that for this time period, because of COVID-19 and the urgency, I think that they are allowing us to do this. Will this be a standard? I hope it becomes a standard. The physics and the physicist team at Holy Name are looking at this as very, very sufficient. They have done the studies of the unit because it was delivered last week, installed this week, and they have done some of the testing on it. And so they are finding that any radiation scatter is no worse than having it in the room so far, so far. But when you’re using it with ICU patients, and they want to get to the patient, and things could change. But over time, we’ll find out the data will be accumulated and we’ll put it together and we’ll see where it goes, but certainly, an opportunity. But I’m also going to give you this point. The cost of that mobile unit was almost more than what it cost to do an entire room.

Okay. So it would be more of eliminate the headache with the regulators rather than cost savings, potentially?

Yes, potentially. So could it be something that we do in the hospitals? Yes. I think that can be done in the hospitals. Can it be done in private settings? Probably not.

Okay, okay. That’s fair. And then you mentioned these disruptive rental strategies, these couple new rental strategies that you have. Can you give us any more color on how the disruptive term applies? And if not, when should we expect to hear more on that front?

Yes. Well, the disruption comes from a customer doesn’t have to buy anything. They don’t have to put out cash to buy a medical device. And therefore, if they rent it, what does that do? So if we’re provided with a service that pays x by them, and we say, okay, we have a fleet of 3, 4, 5 different lasers that they have access to for their various treatments that they have. If they had to buy those 4, 5 lasers, you’re looking at probably $150,000 to $300,000 for them to outlay for those 4 or 5 lasers. We would have an agreement with them that pays x dollars per month over a 2 or 3-year period that certainly wouldn’t come close to that $150,000 to $300,000 period. They wouldn’t have to worry about service contracts. They wouldn’t have to worry about downtime with breakage and things like that. And they would have a fleet of lasers at their fingertips whenever they need it. And I think that that’s an opportunity for them. And I think that’s where the disruption comes, and it’s a great way for us to avoid the competition that exists. And I think some of you are very knowledgeable about the laser business. It has tremendous competition with all the companies out there. We want to provide a different thing for our customers and especially the customers that have multiple sites. We think that we can provide them with something unique.

Sure. Makes sense. And then just finally for me, the mobile van opportunity that you are looking at outside of Florida, is that a single state? Is that in multiple states? Any kind of color you might be able to provide there would be helpful. And then congrats on the quarter guys and the progress as well.

Thank you, Ben. Appreciate it. One of the opportunities that we have already looked at three markets that we are very interested in. I am not going to name what those markets are, but it’s clearly around the cluster of SRT machines that we have in those areas, those pockets. Why? Because we already have a customer base, we have good relationships with those customers. So we want to further develop and expand those markets with other technologies. After all, those are the doctors that asked us, I wish I could buy more stuff from you, and the answer was lasers. So we want to expound on that. So we have already identified several operators in those areas that might be a good fit for us. We’re not looking for the biggest. We’re looking for the best. We want the best management involved. More importantly, we want the ones that have the best relationships with their customers. We strive on those relationships, and we enjoy those relationships, and we want to strengthen them wherever we can. So those are the things that we’re looking at, and we’re seeing signs of this organic growth and building what we already have. And if that continues, we probably want to make some things happen and start conversations in the second quarter to make these things effective in the third quarter, so that at least we have an impact on our revenues for this year because we like the business. Thanks, Ben. Appreciate it.

Thank you.

We will move next to James Terwilliger at Northland Securities.

Hey, Joe. Can you hear me?

Yes, sir, James. How are you doing out there in Memphis?

I’m doing well. First of all, congratulations on a fantastic quarter considering what you were navigating with everything going on I have been jumping between calls, so I apologize if I’ve missed – a lot of things have been covered. I think there have been great questions on this call. I may have missed a few things, though. On the reimbursement side, you talked about CPT 77401 and E&M, Evaluation & Monitoring and the percentage increase. Can you quantify what’s the dollar increase? I mean, my thesis is that clinicians should be gravitating to the SRT for the clinical thesis, but it’s always nice to have a reimbursement tailwind, reimbursement increase, pushing the sales, so to speak, as you move into 2021. What is the – and you have multiple treatments there. So what is the dollar increase? Can you back into that?

Yes. I can go to that. And what I will say is this. Realize that in various parts of the country, there are various levels of that revenue. So it could vary anywhere between $1 and $5 from what CMS has provided as an average across the country. So it could be a little bit more and it could be a little less. Percentage-wise, it’s about a 67% increase in 77401 versus what it was the previous several years. And when it comes to the E&M codes, they have gone up 30%. So the combination of the two, pending what protocols the doctor brings together for the number of treatments he’s going to plan or she’s going to plan on the patient, it’s approximately a 50% increase across the board. So in the last several years, we’ve seen an average reimbursement being somewhere around $2,100 for an average treatment plan of about 14 or 15 fractions. And so now you’re looking at somewhere closer to between $3,200 and $3,800, depending on the number of fractionations that a doctor is going to choose for that treatment plan.

Fantastic. Second question – and I think you talked about this a little bit earlier. I know – I don’t want to box into a corner, but I’m a big fan of Sculptura. And clearly, everyone is talking COVID, but no offense. I just had my college roommate’s wife actually passed away at 50. By the time they caught the cancer, it was in her spine and it had moved within the bone marrow, three different places. It came on the tissue. It was Stage 4 fast moving. He has got three kids. The cancer market is not going away. We’re talking a lot about COVID. How is your – and I know looking backward, it was almost impossible to get to the hospitals in 2020 with the shutdown in COVID to talk about a thing like Sculptura. How do you view Sculptura in 2021 in terms of the excitement around that product? You’ve got some of the best facilities out there using it. You are talking to some of the other – some of the best facilities that I’m sure are interested. How should we think about Sculptura in 2021?

I think that what’s exciting for us is the fact that we had a face-to-face meeting with our friends at UPenn in late January. Our management team on the engineering side felt that it was important to visit them, and they were happy to receive us in spite of all the restrictions in getting into their hospital. And of course, they had to go through all kinds of things to get in with testing and everything else before they even got there and then having everything duplicated by the time they got there. But the enthusiasm for the Sculptura product there has not waned in any way, shape or form. As a matter of fact, it’s almost like being at a horse race and holding the horse into the gate while everybody else has left the gate. This horse wants to catch up and move even faster. So they are more willing than ever to get going with this. So they are as committed as they ever were. However, they are restricted because all of the focus and all of the resources within that hospital are being directed towards COVID. And they are being – and it’s very, very costly, very time-consuming, and very expensive. But here’s what I feel from that meeting. I think that at some point in the second quarter that they are going to get back onto the bandwagon, where we’re going to have a lot of interface with them in the final touches, if you will, of developing exactly what they want because part of that collaboration is them tweaking things to their own personal needs, which we are doing. And that development is pretty much done for the most part. But we just have to put it in there and make it work for them, and everything will be satisfactory. So I see that happening in the second quarter, early in the second quarter. Then I see them finally getting on their protocols, either by the end of the second quarter or early in the third quarter where we should have some data and results of that testing and from those clinical studies that they are going to do on patients with the first set of patients being breast cancer. With that being said, we have got – and we continue to get calls as they continue to get calls as well from hospitals that are very interested in the technology that want to get updates. And so I’m thinking that we have an opportunity maybe to sell a unit, okay, before the end of the year. Not sure it’s going to happen because of hospitals and things like that. And they have got a lot of restrictions on their medical or their device acquisitions on their capital budgets. But if we are able to get a sale, whether it’s within the country or outside the country, I think that we’ve got an opportunity to do that before the end of the year. And then I think that will set us off for a decent 2022 with Sculptura.

Alright. Fantastic. And then lastly, we had these ice storms in Texas and other places in the South, not necessarily Florida, so you guys escaped it. I spoke to a lot of different doctors in Dennis. Their practices were pretty much closed for the week. Did that – is that going to have a major impact on you guys or is that more of kind of a just a push back 1 or 2 weeks, some of the things you are working on?

Well, that impacts the doctors who already have our equipment and the volume of patients that they are already treating. So they will probably have to reengage those patients, redo their treatment planning. It’s nothing for us. But I have to say, and this is not something that we want to have happen, but we did have a customer who had damage to their device because of consequent snow, rain, flooding and that kind of stuff. So there was damage to a unit. They are applying to their insurance. And if the insurance pays for it, we got another unit going. So, not that it’s a negative, it might be a positive, but it’s not the way we want to build our business, but I don’t think it’s holding back any of the decisions other than the time for that week that we weren’t able to see those customers.

Okay, fantastically again congratulations on a great quarter and keep it up. Thanks a lot, Joe for taking my questions. Thank you.

Thanks, James. Appreciate it very much.

And with no other questions holding, I’ll turn the conference back to management for any additional or closing comments.

Thank you, Jess. So in closing, I want to thank you once again for your time this afternoon and for your interest in Sensus. We continue to move forward on multiple fronts and are optimistic about our prospects when we return to a more typical business pattern, and we hope it soon. Before we conclude, I want to let you know that we’ll be participating in 3 virtual conferences later this month. Next week, we’ll be presenting at the H.C. Wainwright Global Conference. The week after that, we’ll be presenting at the ROTH Virtual Conference, followed by the Maxim Virtual Conference shortly after that. We will be issuing a press release to let you know how you can listen to our presentations. If you would like a one-on-one meeting at either of these conferences, please contact your sales rep at either bank and we would be more than happy to accommodate. Again, we want to recognize and thank the many frontline workers who continue to help the many COVID-19 stricken patients. Please stay safe, everyone and thank you so much.

Ladies and gentlemen, that will conclude today’s conference. We thank you so much for your participation. You may disconnect at this time and have a great day.